Dataset from A Multicenter, Open Label, Phase I /Randomised Phase II Study to Evaluate Safety, Pharmacokinetics and Efficacy of BIBF 1120 in Comparison With Oral Sorafenib for Advanced Hepatocellular Carcinoma Patients.
收藏NIAID Data Ecosystem2026-05-02 收录
下载链接：
https://doi.org/10.25934/00003586
下载链接
链接失效反馈官方服务：
资源简介：
The study aim is to determine maximally tolerated dose (MTD) of BIBF 1120 in HCC (hepatocellular cancer) and compare efficacy of BIBF 1120 to Sorafenib in HCC patients
创建时间：
2025-07-31
